<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>M&g Plc — News on 6ix</title>
<link>https://6ix.com/company/mandg-plc</link>
<description>Latest news and press releases for M&g Plc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 08 Apr 2026 12:39:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/mandg-plc" rel="self" type="application/rss+xml" />
<item>
<title>2025 Solvency and Financial Condition Report</title>
<link>https://6ix.com/company/mandg-plc/news/2025-solvency-and-financial-condition-report</link>
<guid isPermaLink="true">https://6ix.com/company/mandg-plc/news/2025-solvency-and-financial-condition-report</guid>
<pubDate>Wed, 08 Apr 2026 12:39:00 GMT</pubDate>
<description>M&G plc has announced the submission of its single group Solvency and Financial Condition Report for the year ended 31 December 2025 to the Prudential Regulation Authority. This report, detailing the company's financial condition, is now available for review on the M&G plc investor relations website.
Disclaimer*</description>
</item>
<item>
<title>Holdings in Company</title>
<link>https://6ix.com/company/mandg-plc/news/holdings-in-company-702</link>
<guid isPermaLink="true">https://6ix.com/company/mandg-plc/news/holdings-in-company-702</guid>
<pubDate>Tue, 24 Mar 2026 16:28:00 GMT</pubDate>
<description>M&G Plc has increased its holding in Ondine Biomedical Inc. to 14.29% of the voting rights, crossing a 1% threshold. This change, effective March 16, 2026, represents a total of 74,268,775 voting rights. The previous notification showed a holding of 13.04%. The notification was made on March 17, 2026, and the increase is due to movements within M&G Plc's controlled undertakings.
Disclaimer*</description>
</item>
<item>
<title>Board Committee Changes</title>
<link>https://6ix.com/company/mandg-plc/news/board-committee-changes-19</link>
<guid isPermaLink="true">https://6ix.com/company/mandg-plc/news/board-committee-changes-19</guid>
<pubDate>Tue, 17 Mar 2026 09:00:00 GMT</pubDate>
<description>M&G plc has announced changes to its Board Committees, effective April 1, 2026, with Clive Adamson joining the Remuneration Committee. Additionally, Non-Executive Directors Paul Evans, Dev Sanyal, Elisabeth Stheeman, and Massimo Tosato have been appointed to the Nomination and Governance Committee, which will now comprise all of the Company's Non-Executive Directors. These committee adjustments are the primary focus of this announcement.
Disclaimer*</description>
</item>
<item>
<title>2025 Annual Report and Accounts</title>
<link>https://6ix.com/company/mandg-plc/news/2025-annual-report-and-accounts-2</link>
<guid isPermaLink="true">https://6ix.com/company/mandg-plc/news/2025-annual-report-and-accounts-2</guid>
<pubDate>Thu, 12 Mar 2026 07:00:00 GMT</pubDate>
<description>M&G plc has released its 2025 Annual Report and Accounts, which is now available on their website and has been submitted to the Financial Conduct Authority. The company has declared a second interim dividend of 13.8 pence per share, bringing the total dividend for the year to 20.5 pence, with payment scheduled for April 30, 2026. The ex-dividend date is March 19, 2026, and the record date is March 20, 2026.
Disclaimer*</description>
</item>
<item>
<title>Total Voting Rights</title>
<link>https://6ix.com/company/mandg-plc/news/total-voting-rights-138</link>
<guid isPermaLink="true">https://6ix.com/company/mandg-plc/news/total-voting-rights-138</guid>
<pubDate>Mon, 02 Mar 2026 16:15:00 GMT</pubDate>
<description>M&G plc has announced its total voting rights and issued share capital as of 28 February 2026. The company's issued share capital consists of 2,412,962,560 ordinary shares, with 3,414,030 shares held in treasury, resulting in a total of 2,409,548,530 voting rights. Between 19 January 2026 and 28 February 2026, M&G plc issued 305,892 ordinary shares under its Sharesave Plan 2019, which are fully fungible with existing shares and have been admitted to trading on the London Stock Exchange.
</description>
</item>
<item>
<title>TR-1: Notification of Major Holdings</title>
<link>https://6ix.com/company/mandg-plc/news/tr-1-notification-of-major-holdings-102</link>
<guid isPermaLink="true">https://6ix.com/company/mandg-plc/news/tr-1-notification-of-major-holdings-102</guid>
<pubDate>Thu, 26 Feb 2026 15:33:00 GMT</pubDate>
<description>M&G Plc has acquired a new holding in Mony Group PLC, crossing a notification threshold on February 23, 2026. Following this acquisition, M&G Plc now holds a total of 5.221168% of Mony Group PLC's voting rights, comprising 4.184543% directly attached to shares and 1.036625% through financial instruments, specifically lent shares with a right of recall. This represents an increase from their previous notification where they held 4.913502% of voting rights.
Disclaimer*</description>
</item>
<item>
<title>M&G’s response to Leasehold Reform Bill</title>
<link>https://6ix.com/company/mandg-plc/news/mandgs-response-to-leasehold-reform-bill</link>
<guid isPermaLink="true">https://6ix.com/company/mandg-plc/news/mandgs-response-to-leasehold-reform-bill</guid>
<pubDate>Tue, 27 Jan 2026 08:10:00 GMT</pubDate>
<description>M&G PLC has announced its response to proposed changes to ground rents in England and Wales, which are expected to cap existing annual ground rents at £250 from 2028, eventually reducing them to zero. The company is directly exposed to £722 million in ground rent assets through its Prudential Assurance Company shareholder fund. While M&G reconfirms its adjusted operating profit growth and capital generation targets, the proposed changes could lead to a £230 million one-off reduction in Group Sol</description>
</item>
<item>
<title>Director/PDMR Shareholding</title>
<link>https://6ix.com/company/mandg-plc/news/directorpdmr-shareholding-179</link>
<guid isPermaLink="true">https://6ix.com/company/mandg-plc/news/directorpdmr-shareholding-179</guid>
<pubDate>Tue, 13 Jan 2026 15:45:00 GMT</pubDate>
<description>M&G plc announced that on January 9, 2026, two Persons Discharging Managerial Responsibilities (PDMRs), Charlotte Heiss and Matthew Howells, purchased partnership shares and were granted matching shares under the M&G UK Share Incentive Plan. Heiss, Group General Counsel and Company Secretary, and Howells, Chief People Officer, each acquired a total of 76 ordinary shares at an average price of £2.949 per share, with individual purchase prices of £2.942 and £2.964 for partnership and matching shar</description>
</item>
<item>
<title>Holding(s) in Company</title>
<link>https://6ix.com/company/mandg-plc/news/holdings-in-company-180</link>
<guid isPermaLink="true">https://6ix.com/company/mandg-plc/news/holdings-in-company-180</guid>
<pubDate>Tue, 13 Jan 2026 15:30:00 GMT</pubDate>
<description>M&G Plc has notified Sirius Real Estate Limited that on January 12, 2026, its total holding of voting rights and financial instruments crossed a threshold, resulting in a combined holding of 5.159066%. This comprises 4.954031% of direct voting rights attached to shares and 0.205035% through financial instruments, specifically lent shares with a right of recall. This represents a decrease from their previous notification where their total holding was also 5.159066%, but the direct voting rights w</description>
</item>
<item>
<title>M&G champions UK innovation in drug discovery by leading US$50 million funding round for biotech company bit.bio</title>
<link>https://6ix.com/company/mandg-plc/news/m-g-champions-uk-innovation-173100416</link>
<guid isPermaLink="true">https://6ix.com/company/mandg-plc/news/m-g-champions-uk-innovation-173100416</guid>
<pubDate>Fri, 09 Jan 2026 17:31:00 GMT</pubDate>
<description>M&G Investments (M&G) today announces that it has led a US$50 million Series C funding round for bit.bio, the Cambridge-based biotech company pioneering next-generation human cell programming technology. The investment of patient capital into a fast-growing private UK company, spun out from the University of Cambridge, marks a major vote of confidence in innovation and the future of drug development in the UK.</description>
</item>
<item>
<title>Life insurance stress test</title>
<link>https://6ix.com/company/mandg-plc/news/life-insurance-stress-test</link>
<guid isPermaLink="true">https://6ix.com/company/mandg-plc/news/life-insurance-stress-test</guid>
<pubDate>Mon, 24 Nov 2025 07:06:00 GMT</pubDate>
<description>M&G plc has demonstrated its financial resilience through the Prudential Regulation Authority's 2025 Life Insurance Stress Test, with its Group Shareholder ratio projected to decrease from 223% to 171% under a severe three-stage stress scenario, remaining within its target range of 160-190%. The in-scope entity, Prudential Assurance Company Ltd (PAC), also showed continued capitalisation, with its Shareholder ratio falling from 214% to 151% and its Regulatory ratio decreasing from 157% to 122%, </description>
</item>
<item>
<title>M&G plc Q3 2025 trading update</title>
<link>https://6ix.com/company/mandg-plc/news/mandg-plc-q3-2025-trading-update</link>
<guid isPermaLink="true">https://6ix.com/company/mandg-plc/news/mandg-plc-q3-2025-trading-update</guid>
<pubDate>Wed, 05 Nov 2025 07:00:00 GMT</pubDate>
<description>M&G PLC reported a strong Q3 2025 trading update, with Group Assets Under Management and Administration increasing 3% to £
Disclaimer*</description>
</item>
<item>
<title>Block listing Interim Review</title>
<link>https://6ix.com/company/mandg-plc/news/block-listing-interim-review-83</link>
<guid isPermaLink="true">https://6ix.com/company/mandg-plc/news/block-listing-interim-review-83</guid>
<pubDate>Fri, 31 Oct 2025 10:30:00 GMT</pubDate>
<description>M&G plc reported a block listing six-monthly return on October 31, 2025. For the M&G plc Sharesave Plan 2019, covering the period from April 30, 2025, to October 31, 2025, the balance of unallotted securities from the previous return was 7,490,419. During this period, 433,232 securities were issued/allotted, leaving a balance of 7,057,187 unallotted securities. For the M&G plc Deferred Incentive Plan 2019 and M&G plc Performance Share Plan 2019, no securities were issued or allotted during the p</description>
</item>
<item>
<title>Notification of major holdings - M&G</title>
<link>https://6ix.com/company/mandg-plc/news/notification-of-major-holdings-mandg</link>
<guid isPermaLink="true">https://6ix.com/company/mandg-plc/news/notification-of-major-holdings-mandg</guid>
<pubDate>Thu, 04 Sep 2025 16:23:00 GMT</pubDate>
<description>M&G Plc has crossed a threshold requiring notification regarding its holdings in Ondine Biomedical Inc. As of September 3, 2025, M&G Plc holds 12.974380% of the voting rights attached to shares, representing 67,254,901 voting rights. This is an increase from the previously notified position of 9.182066%. The voting rights are held indirectly through a chain of controlled undertakings, including M&G Group Regulated Entity Holding Company Limited, M&G Group Limited, M&G FA Limited and M&G Investme</description>
</item>
<item>
<title>M&G plc Half Year 2025 Results</title>
<link>https://6ix.com/company/mandg-plc/news/mandg-plc-half-year-2025-results</link>
<guid isPermaLink="true">https://6ix.com/company/mandg-plc/news/mandg-plc-half-year-2025-results</guid>
<pubDate>Wed, 03 Sep 2025 06:00:00 GMT</pubDate>
<description>M&G PLC reported strong net flows from open business of £2.1 billion for the first half of 2025, a significant £3.2 billion improvement compared to the £1.1 billion outflow in H1 2024. The asset management cost-to-income ratio improved from 77% to 75%. Adjusted operating profit before tax was £378 million, slightly up from £375 million in the previous year. Operating capital generation remained strong at £408 million, although lower than the £486 million in H1 2024. The shareholder Solvency II r</description>
</item>
<item>
<title>Dai-ichi Life and M&G form strategic partnership</title>
<link>https://6ix.com/company/mandg-plc/news/dai-ichi-life-and-mandg-form-strategic-partnership</link>
<guid isPermaLink="true">https://6ix.com/company/mandg-plc/news/dai-ichi-life-and-mandg-form-strategic-partnership</guid>
<pubDate>Fri, 30 May 2025 06:00:00 GMT</pubDate>
<description>Dai-ichi Life and M&G form strategic partnership.</description>
</item>
<item>
<title>Result of AGM</title>
<link>https://6ix.com/company/mandg-plc/news/result-of-agm-153</link>
<guid isPermaLink="true">https://6ix.com/company/mandg-plc/news/result-of-agm-153</guid>
<pubDate>Wed, 30 Apr 2025 12:35:00 GMT</pubDate>
<description>Result of AGM.</description>
</item>
<item>
<title>2024 Solvency and Financial Condition Report</title>
<link>https://6ix.com/company/mandg-plc/news/2024-solvency-and-financial-condition-report</link>
<guid isPermaLink="true">https://6ix.com/company/mandg-plc/news/2024-solvency-and-financial-condition-report</guid>
<pubDate>Fri, 04 Apr 2025 16:45:00 GMT</pubDate>
<description>2024 Solvency and Financial Condition Report.</description>
</item>
<item>
<title>Notice of AGM</title>
<link>https://6ix.com/company/mandg-plc/news/notice-of-agm-55</link>
<guid isPermaLink="true">https://6ix.com/company/mandg-plc/news/notice-of-agm-55</guid>
<pubDate>Wed, 26 Mar 2025 10:00:00 GMT</pubDate>
<description>Notice of AGM.</description>
</item>
<item>
<title>2024 Annual Report and Accounts</title>
<link>https://6ix.com/company/mandg-plc/news/2024-annual-report-and-accounts</link>
<guid isPermaLink="true">https://6ix.com/company/mandg-plc/news/2024-annual-report-and-accounts</guid>
<pubDate>Wed, 19 Mar 2025 07:01:00 GMT</pubDate>
<description>2024 Annual Report and Accounts.</description>
</item>
</channel>
</rss>